You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

PLASMA & BIOTHERAPIES

First patient enrolled and treated in Kedrion’s CARES10 clinical study

Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

read more 

EVENTS

June 27 and 28 in Trieste (Italy), a two-day event dedicated to hemophilia

Replacement therapy, personalization and access to treatment are the main themes of the congress organized by Kedrion

read more 

EVENTS

16th International Hemophilia Congress in Turkey

A scientific symposium on the prevention and eradication of inhibitors in patients affected by Hemophilia A

read more 
  1. CORPORATE - 30-04-2015

    Kedrion SpA’s Shareholders approve 2014 financial statement

    A 466 million euros’ turnover with a 9,8% rise on 2013

    read more 
  2. EVENTS - 17-04-2015

    Kedrion supported the XI World Hemophilia Day

    An increasingly tailor-made prophylaxis lets sports and hemorrhagic conditions live together

    read more 
  3. CORPORATE - 27-02-2015

    Kedrion unveils its new manufacturing plant in Castelvecchio Pascoli

    The company has invested over 67 million euros and is expected to create between 70 and 90 new jobs

    read more 

Pages

For more information please contact: pressoffice@kedrion.com